Compass Pathways plc has completed its New Drug Application submission to the U.S. Food and Drug Administration for COMP360, its investigational synthetic psilocybin formulation for treatment-resistant depression, moving one of the most advanced psychedelic drug programmes into formal regulatory review. The filing is supported by two Phase 3 studies, COMP005 and COMP006, together with the earlier Phase 2b programme, encompassing more than 1,000 participants across the clinical-development package.
The milestone does not mean the FDA has accepted the application for review or approved COMP360. Compass had been submitting the NDA on a rolling basis and has now completed the remaining components, leaving the regulator to determine whether the application is sufficiently complete for formal review and ultimately whether the efficacy, safety, treatment-delivery and manufacturing package supports marketing authorisation.
If approved, COMP360 could become the first FDA-approved psilocybin-based medicine and would represent an unusually consequential test for psychedelic drug development. The regulatory decision would involve not only the pharmacology of a new psychiatric treatment but a care model requiring psychological support, trained providers, controlled administration and prolonged observation during dosing sessions.
What do the two Phase 3 trials actually show about COMP360 in treatment-resistant depression?
COMP005 evaluated a single 25 mg dose of COMP360 against placebo in 258 dosed participants with treatment-resistant depression. At Week 6, the 25 mg group showed a 3.6-point greater improvement than placebo on the Montgomery-Åsberg Depression Rating Scale, with the difference reaching statistical significance below p=0.001.
The treatment effect emerged rapidly, with statistically significant separation reported from the day after administration and maintained across measured time points through Week 6. Baseline MADRS scores were about 31.5 in both treatment groups, reflecting substantial depressive symptom burden at study entry.
COMP006 provided an independent test using a different design. The trial enrolled 581 participants and compared two fixed doses of 25 mg COMP360, administered three weeks apart, with 10 mg and 1 mg regimens. At Week 6, the 25 mg arm produced a 3.8-point greater reduction in MADRS score compared with the 1 mg control arm, again with p below 0.001.
The consistency between two separately conducted pivotal studies is important because psychedelic trials face unusual challenges around blinding, participant expectations and treatment setting. Both trials met their prespecified primary endpoints, strengthening the evidentiary package compared with relying on one positive pivotal study or an uncontrolled dataset.
Why does the magnitude of the MADRS difference require more nuance than the statistical result?
Statistical significance establishes that the observed differences were unlikely to be explained by chance under the trial assumptions, but it does not automatically establish that every patient experiences a large or durable improvement. The placebo-adjusted differences of 3.6 points in COMP005 and 3.8 points in COMP006 therefore need to be considered alongside responder analyses, treatment durability and the severity of the population enrolled.
In COMP006, 39% of participants receiving 25 mg achieved what Compass defined as a clinically meaningful reduction in MADRS of at least 25% at Week 6. The company also reported that participants meeting this threshold maintained benefit on average through at least Week 26, while some patients who had not entered remission after the initial treatment later did so following retreatment.
COMP005 produced a lower proportion meeting that particular post hoc durability definition at Week 6, at roughly 25% in the 25 mg arm. Longer-term open-label follow-up subsequently suggested additional benefit when eligible participants received another 25 mg dose, with response rates of around 40% to 45% and remission rates of approximately 30% during the six weeks after open-label retreatment.
These longer-term findings support the idea that some patients may benefit from intermittent retreatment rather than continuous daily medication. However, the 52-week portion of COMP005 was open label, making it less rigorous than the blinded primary Phase 3 comparison and unsuitable for treating one-year durability as independently confirmed placebo-controlled evidence.
Why could COMP360’s treatment model be as important to the FDA as the drug itself?
COMP360 is not being developed like a conventional antidepressant tablet taken at home every day. Psilocybin produces acute alterations in perception, cognition and emotional processing, meaning administration occurs within a structured clinical setting with preparation, psychological support and monitoring.
The treatment session can last several hours, creating operational requirements that extend well beyond writing a prescription. Providers need training, treatment rooms must be available for extended periods, patients require supervision during the psychoactive experience, and clinics must determine how to manage throughput economically.
Compass argues that the United States already has thousands of centres capable of delivering multi-hour behavioural or psychiatric treatments. Existing infrastructure associated with treatments such as ketamine, esketamine and neuromodulation could provide a starting point, but COMP360 would still require its own provider training, protocols and reimbursement arrangements.
This makes commercial adoption fundamentally different from most oral antidepressant launches. Even if the FDA approves COMP360, the rate of uptake could be constrained by clinic capacity, patient scheduling, reimbursement, provider availability and the economics of occupying a treatment room for much of a working day.
What does the COMP360 safety dataset show across Phase 3 development?
COMP360’s safety assessment is especially important because treatment-resistant depression is associated with elevated baseline risk of suicidal ideation and behaviour, while psilocybin itself produces acute psychological and perceptual effects that require controlled administration.
Across the Phase 3 programme, commonly reported treatment-emergent adverse events included headache, nausea, anxiety and visual hallucinations. Most adverse events associated with dosing were transient and occurred during or shortly after the treatment session, according to the company’s disclosed data.
In COMP006 through 26 weeks, serious treatment-emergent adverse events occurred in 5.7% of patients receiving 25 mg COMP360 compared with 6.3% in the 1 mg control arm. Serious suicidal ideation occurred in 1.4% of patients in the 25 mg group and 2.8% in the 1 mg group, while one suicidal-behaviour event was reported in the 25 mg arm.
The programme also recorded individual serious events including suicide attempts and other psychiatric or medical events. These occurrences do not establish that COMP360 caused them, particularly in a population with severe and chronic depression, but they make careful post-treatment monitoring and regulatory scrutiny essential.
An approval decision will therefore depend on more than the absence of a single dominant safety signal. The FDA will evaluate whether the supervised treatment framework, exclusion criteria, provider training and monitoring requirements sufficiently manage acute psychological effects and longer-term psychiatric risk.
Why does the NDA matter more than another positive psychedelic trial announcement?
Psychedelic drug development has generated substantial investor and public attention, but many programmes remain early stage. Compass has now moved beyond proof of concept, Phase 2 enthusiasm and conference presentations into the regulatory process that determines whether psilocybin can become an approved medical treatment in the United States.
Completing the NDA transforms the central question. The issue is no longer simply whether COMP360 can produce statistically significant improvement in treatment-resistant depression, because two Phase 3 studies have already answered that within their prespecified primary analyses.
The regulatory debate instead moves toward whether the magnitude and durability of benefit justify the treatment burden and acute psychoactive effects, whether retreatment can be managed consistently, and whether the entire treatment protocol is reproducible outside clinical trials.
FDA acceptance of the application would be the next formal milestone. Approval remains uncertain until the regulator completes its review, potentially requests additional information and evaluates the full clinical, manufacturing and risk-management package.
Could DEA scheduling become another hurdle even after an FDA approval?
Psilocybin remains a controlled substance under U.S. federal law. Compass has therefore indicated that commercial launch would require not only FDA approval but appropriate Drug Enforcement Administration rescheduling before COMP360 could be distributed and used as an approved medicine.
That process creates an additional operational step that does not exist for most psychiatric drug launches. Manufacturing, transport, storage, prescribing and administration may all involve controlled-substance requirements that clinics must be equipped to manage.
Compass currently expects a potential launch in the first half of 2027, subject to FDA approval and required scheduling actions. That timeline represents management’s planning assumption rather than a confirmed commercial launch date because both regulatory processes remain outside the company’s direct control.
The scheduling requirement also reinforces why COMP360 should not be viewed simply as pharmaceutical psilocybin placed into ordinary pharmacy distribution. The likely commercial model involves tightly controlled delivery through authorised healthcare settings rather than routine unsupervised take-home use.
How strong is Compass Pathways’ financial position ahead of a possible launch?
Compass reported $444 million in cash and cash equivalents at September 30, 2026 and has said the balance should fund planned operating expenses and capital expenditures into 2028. That gives the company an unusually substantial cash cushion for a biotechnology business approaching its first potential commercial launch.
Third-quarter research and development expenses were $23.5 million, while selling, general and administrative expenses rose to $33 million. The increasing commercial expenditure reflects the company’s transition from a development-stage organisation towards one preparing provider training, market access, reimbursement and launch infrastructure.
A psychedelic launch could require considerable upfront investment because Compass must build not only demand for a medicine but a network capable of administering it. Training centres, educating psychiatrists, securing payer coverage and establishing operational standards could consume capital before sales meaningfully offset expenditure.
The $444 million balance therefore reduces immediate financing pressure but does not eliminate commercial execution risk. A slower-than-expected FDA review, restrictive label or reimbursement delays could extend the period between launch investment and meaningful revenue.
Why has Compass Pathways stock remained volatile despite reaching the NDA stage?
Compass Pathways shares closed at approximately $9.25 on November 10, leaving the company with a market capitalisation of about $1.31 billion. The stock gained 6.6% on November 9 when completion of the NDA was announced before edging modestly higher in the following session.
The shares were up roughly 8% over the preceding week but remained around 20% lower over one month and about 42% below the 52-week high of $15.87. The 52-week trading range extended down to $4.88, illustrating how dramatically investor expectations around COMP360 have shifted during 2026.
That volatility reflects the binary nature of the programme. Compass has no established commercial pharmaceutical franchise capable of cushioning a negative regulatory outcome, while COMP360 represents the central value driver behind the company’s valuation and planned commercial organisation.
The NDA submission removes development-stage uncertainty around whether Compass could assemble the application, but it introduces a different set of questions around FDA review, treatment labelling, controlled-substance logistics, reimbursement and the pace of physician adoption.
Can COMP360 become a commercial psychiatric treatment rather than a specialist psychedelic procedure?
The clinical programme has moved COMP360 closer to regulatory review than almost any classic psychedelic therapy developed under modern pharmaceutical standards. Two Phase 3 trials have met their primary endpoints, treatment effects appeared rapidly and follow-up suggests that some responders can maintain benefit for months or respond again after additional dosing.
Commercial success will require something much harder than repeating those clinical results. Compass must convert a highly structured trial procedure into a scalable healthcare service that insurers will fund, providers can deliver efficiently and patients can access without waiting for scarce specialist appointments.
The potential advantage is a treatment model based on infrequent dosing rather than daily medication. For patients who respond durably after one or several supervised sessions, that could offer a fundamentally different approach to treatment-resistant depression. The disadvantages are equally structural, including prolonged treatment sessions, acute psychoactive effects, training requirements and controlled-substance regulation.
The NDA now puts those questions directly before the FDA. If COMP360 is accepted and ultimately approved, Compass Pathways will face an even more consequential test: proving that the clinical effect demonstrated across more than 1,000 trial participants can be reproduced safely and economically across ordinary psychiatric practice.
